AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca is conducting a Phase III clinical study titled ‘A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations.’ The study aims to compare the efficacy and safety of Dato-DXd combined with durvalumab and carboplatin against pembrolizumab with platinum-based chemotherapy in treating advanced non-small cell lung cancer (NSCLC) without actionable genomic alterations.
The intervention being tested involves a combination of drugs: Datopotamab Deruxtecan (Dato-DXd), Durvalumab, and Carboplatin. These are intended to provide a first-line treatment option for patients with advanced NSCLC, aiming to improve progression-free survival (PFS) and overall survival (OS) compared to existing therapies.
This interventional study follows a randomized, open-label, parallel assignment model with no masking. The primary purpose is treatment, focusing on comparing the new drug combination’s efficacy against the current standard of care.
The study began on December 29, 2022, and is not currently recruiting participants. The last update was submitted on July 1, 2025. These dates are crucial for tracking the study’s progress and understanding its timeline in the context of drug development and approval processes.
For investors, this study’s outcome could significantly impact AstraZeneca’s stock performance, especially if the results demonstrate superior efficacy of the new drug combination. Positive results could enhance AstraZeneca’s competitive position in the oncology market, potentially affecting investor sentiment and market dynamics, particularly against competitors offering similar treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.